目的:探讨宫腔镜检查在子宫内膜癌患者中的诊断价值,分析其是否增加子宫内膜癌细胞的腹腔内播散及对患者临床结局的影响。方法:计算机检索Pubmed、Web of science、Elsevier、CNKI等数据库,搜集子宫内膜癌患者术前进行和未进行宫腔镜检...目的:探讨宫腔镜检查在子宫内膜癌患者中的诊断价值,分析其是否增加子宫内膜癌细胞的腹腔内播散及对患者临床结局的影响。方法:计算机检索Pubmed、Web of science、Elsevier、CNKI等数据库,搜集子宫内膜癌患者术前进行和未进行宫腔镜检查的随机对照或病例对照实验。采用Rev Man 5.3及Stata12.0软件进行Meta分析。结果:共纳入22篇文献,共7127例子宫内膜癌患者。Meta分析结果显示,子宫内膜癌患者术前行宫腔镜检查组与未行宫腔镜检查组比较,不增加患者癌细胞腹腔内播散的风险(OR=1.61,95%CI为0.94~1.43,P=0.18)。宫腔镜检查组中,腹腔冲洗液细胞学阳性率与采用的膨宫介质相关,液体膨宫介质增加腹腔冲洗液肿瘤细胞阳性率,且使用盐水时最显著(OR=1.54,95%CI为1.08~2.19,P=0.02)。对3篇文献合并分析两组的5年总存活率及无病生存率,HR分别为1.28(0.75~2.17)和1.17(0.63~2.15)。结论:子宫内膜癌患者术前行宫腔镜检查能提高诊断准确性,且不增加癌细胞的腹腔内播散,亦无证据表明宫腔镜检查可导致不良临床结局,是较理想的检测手段;盐水等液体介质是腹腔冲洗液细胞学阳性的高危因素之一,应慎用。展开更多
The International Federation of Gynecology and Obstetrics (FIGO) changed the surgical staging criteria for endometrial cancer in 2009, namely combining FIGO 1988 Stage IA and IB in FIGO 2009 Stage IA, eliminating cerv...The International Federation of Gynecology and Obstetrics (FIGO) changed the surgical staging criteria for endometrial cancer in 2009, namely combining FIGO 1988 Stage IA and IB in FIGO 2009 Stage IA, eliminating cervical glandular involvement from Stage II, and removing peritoneal cytology as criteria from Stage IIIA (3). This review of the literature sheds light on the continued debate among authorities on the utility of peritoneal cytology in surgical staging of endometrial cancer. At the time FIGO removed peritoneal cytology from the staging criteria in 2009, there was little to no evidence to support its removal. In fact, FIGO continues to recommend obtaining peritoneal cytology, which is in contradiction to their staging criteria. While a few small studies support the idea that peritoneal cytology does not preclude a worse prognosis, a number of large scale studies with at least 300 patients demonstrate a clear association between survival and the presence of malignant peritoneal cytology (11 - 12, 15 - 19). In one of the largest studies, investigators reviewed 14,704 from the SEER’s database, demonstrating that malignant peritoneal cytology is associated with decreased survival across Stage I/II disease even when controlled for histology, grade, and other risk factors. Malignant peritoneal cytology should be considered when counseling patients on the risk of recurrence and overall survival of endometrial cancer. However, the role of adjuvant treatment in this setting remains unclear.展开更多
文摘目的:探讨宫腔镜检查在子宫内膜癌患者中的诊断价值,分析其是否增加子宫内膜癌细胞的腹腔内播散及对患者临床结局的影响。方法:计算机检索Pubmed、Web of science、Elsevier、CNKI等数据库,搜集子宫内膜癌患者术前进行和未进行宫腔镜检查的随机对照或病例对照实验。采用Rev Man 5.3及Stata12.0软件进行Meta分析。结果:共纳入22篇文献,共7127例子宫内膜癌患者。Meta分析结果显示,子宫内膜癌患者术前行宫腔镜检查组与未行宫腔镜检查组比较,不增加患者癌细胞腹腔内播散的风险(OR=1.61,95%CI为0.94~1.43,P=0.18)。宫腔镜检查组中,腹腔冲洗液细胞学阳性率与采用的膨宫介质相关,液体膨宫介质增加腹腔冲洗液肿瘤细胞阳性率,且使用盐水时最显著(OR=1.54,95%CI为1.08~2.19,P=0.02)。对3篇文献合并分析两组的5年总存活率及无病生存率,HR分别为1.28(0.75~2.17)和1.17(0.63~2.15)。结论:子宫内膜癌患者术前行宫腔镜检查能提高诊断准确性,且不增加癌细胞的腹腔内播散,亦无证据表明宫腔镜检查可导致不良临床结局,是较理想的检测手段;盐水等液体介质是腹腔冲洗液细胞学阳性的高危因素之一,应慎用。
文摘The International Federation of Gynecology and Obstetrics (FIGO) changed the surgical staging criteria for endometrial cancer in 2009, namely combining FIGO 1988 Stage IA and IB in FIGO 2009 Stage IA, eliminating cervical glandular involvement from Stage II, and removing peritoneal cytology as criteria from Stage IIIA (3). This review of the literature sheds light on the continued debate among authorities on the utility of peritoneal cytology in surgical staging of endometrial cancer. At the time FIGO removed peritoneal cytology from the staging criteria in 2009, there was little to no evidence to support its removal. In fact, FIGO continues to recommend obtaining peritoneal cytology, which is in contradiction to their staging criteria. While a few small studies support the idea that peritoneal cytology does not preclude a worse prognosis, a number of large scale studies with at least 300 patients demonstrate a clear association between survival and the presence of malignant peritoneal cytology (11 - 12, 15 - 19). In one of the largest studies, investigators reviewed 14,704 from the SEER’s database, demonstrating that malignant peritoneal cytology is associated with decreased survival across Stage I/II disease even when controlled for histology, grade, and other risk factors. Malignant peritoneal cytology should be considered when counseling patients on the risk of recurrence and overall survival of endometrial cancer. However, the role of adjuvant treatment in this setting remains unclear.
